Johnson & Johnson (NYSE:JNJ) is one of the largest and most prolific drugmakers, and its stock is a staple in dividend portfolios.
However, patent expiration has created revenue headwinds that the company will need to overcome with newly launched drugs, especially as one of its top-selling treatments loses patent protection in Europe in 2015. Dividend investors are also right to wonder whether Johnson & Johnson's profitability, which has slipped in recent years due to higher spending, threatens its dividend strategy.
In the following slideshow, you'll learn how Johnson & Johnson is navigating the patent cliff for revenue growth, see what may be in store for its margins, and discover how the company stacks up to competitors such Merck and Bristol-Myers Squibb when it comes to dividend payouts.
Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned.The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.